Kapruvia? approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
? First approved therapy in Europe for the treatment of chronic
kidney disease (CKD)-associated pruritus in hemodialysis patients
? First launches in Europe expected in H2 2022
ST. GALLEN, Switzerland & STAMFORD, Conn. -- (BUSINESS WIRE) --
Regulatory News:
This press release features multimedia. View the full release here: //www.mtescar.com
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia? (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients. The marketing authorization, which approves Kapruvia? for use in all member states of the European Union plus Iceland, Liechtenstein and Norway, follows the U.S. Food and Drug Administration (FDA) approval of KORSUVA? (difelikefalin) injection in August 2021 for the same indication. Kapruvia? will be the first therapy available in Europe for the treatment of CKD-associated pruritus in hemodialysis patients.
“We are very excited about the European Commission’s approval of Kapruvia?, marking an important milestone on our journey to advance and fundamentally change the treatment paradigm for people living with the severe burden of pruritus associated with chronic kidney disease,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “We look forward to bringing this first-in-class therapy to patients in Europe, with launch in first markets expected in the second half of 2022.”
“The European Commission’s approval of Kapruvia? provides a much-needed therapy to hemodialysis patients in Europe who suffer from pruritus,” said Dr. Joana Goncalves, Chief Medical Officer of Cara Therapeutics. “We are excited to bring an innovative drug to physicians to help change the way pruritus is managed. We continue to work with our commercial partner VFMCRP, to fill a significant unmet medical need among CKD patients with pruritus in both the U.S. and Europe.”
The approval in Europe is based on pivotal clinical data from two phase-III trials, KALM-1 and KALM-2, as well as supportive data from an additional 32 clinical studies. These studies showed that treatment with Kapruvia? resulted in clinically meaningful improvements in pruritus severity and in pruritus-related quality of life components and was found to be generally well tolerated in patients with moderate-to-severe CKD-associated pruritus.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to
become the global leader in iron deficiency and nephrology. The company
is a partner of choice for pharmaceuticals and innovative
patient-focused solutions across iron, dialysis, nephrology and rare
conditions. Vifor Pharma Group strives to help patients around the world
with severe, chronic and rare diseases lead better, healthier lives. It
specializes in strategic global partnering, in-licensing and
developing, manufacturing and marketing pharmaceutical products for
precision patient care. Vifor Pharma Group holds a leading position in
all its core business activities and includes the companies: Vifor
Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal
Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group
is headquartered in Switzerland and listed on the Swiss Stock Exchange
(SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information,
please visit 鸭脖娱乐APP下载?
For more information, please visit 利来国际平台.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage biopharmaceutical
company leading a new treatment paradigm to improve the lives of
patients suffering from pruritus. The Company’s novel KORSUVA?
(difelikefalin) injection is the first and only FDA-approved treatment
for moderate-to-severe pruritus associated with chronic kidney disease
in adults undergoing hemodialysis. The Company is developing an oral
formulation of difelikefalin and has initiated Phase 3 programs for the
treatment of pruritus in patients with non-dialysis dependent advanced
chronic kidney disease and atopic dermatitis. Phase 2 trials of oral
difelikefalin are ongoing in primary biliary cholangitis and notalgia
paresthetica patients with moderate-to-severe pruritus. For more
information, visit www.CaraTherapeutics.com and follow the company on 九游会集团, 鸭博娱乐APP and j9九游会官网.
About Chronic Kidney Disease-associated Pruritus
CKD-associated pruritus is an intractable systemic itch condition that
occurs with high frequency and intensity in patients with chronic kidney
disease undergoing dialysis. Pruritus has also been reported in
patients with stage III-V CKD who are not on dialysis. The majority of
dialysis patients (approximately 60 to 70%) report pruritus, with 30 to
40% reporting moderate or severe pruritus.1,2,3 Data from the ITCH National Registry Study showed that among those with pruritus, approximately 59%4 experienced symptoms daily or nearly daily for more than a year.
Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years, with currently employed antipruritic treatments, such as antihistamines and corticosteroids, unable to provide consistent, adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression.4 CKD-associated pruritus is also an independent predictor of mortality and the risk for hospitalization among hemodialysis patients.
Forward-looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Examples of
these forward-looking statements include statements concerning the
potential timeline for the launch of difelikefalin solution for
injection in Europe and the potential of difelikefalin solution for
injection to be a therapeutic option for CKD-aP in dialysis dependent
patients. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those expressed
or implied by such forward-looking statements. Risks are described more
fully in Cara's filings with the Securities and Exchange Commission,
including the "Risk Factors" section of Cara's Annual Report on Form
10-K for the year ended 31 December 2021 and its other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except to the
extent required by law, Cara undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
References:
1 Pisoni RL, et al. Pruritus in haemodialysis patients:
international results from the Dialysis Outcomes and Practice Patterns
Study. Nephrol Dial Transplant. 2006; 21:3495-3505.
2 Ramakrishnan K, et al. Clinical characteristics and
outcomes of end-stage renal disease patients with self-reported pruritus
symptoms. International Journal of Nephrology and Renovascular Disease.
2014; 7: 1-12.
3 Sukul et al. Self-reported Pruritus and Clinical,
Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis
Patients. Kidney Med. 2020 Nov 21;3(1):42-53.
4 Mathur VS, et al. A longitudinal study of Uremic Pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1410-1419.
